
About Brawnpharma
Brawnpharma is a publicly listed company based in Delhi (India) founded in 1985. Pharmaceutical products are developed and distributed by Brawnpharma. Its Indian entity Brawn Biotech Limited reported revenue of βΉ17.43 Cr.
Company details
Brawnpharma was established in 1985 in Delhi, India, within the pharmaceutical sector. Operations are centered on the development, manufacturing, and distribution of medicinal products. Services include formulation and supply to healthcare markets. The company is headquartered in Delhi, with activities spanning the Indian pharmaceutical industry. Limited public details are available regarding specific product lines or expansions.
- Headquarters Delhi, India
- Stage Public
- Website brawnpharma.com
- Legal Name Brawn Biotech Limited
- Date of Incorporation 07 Nov, 1985
- Jurisdiction Delhi, India
- Market Cap₹6.30 Cr
BRAWN · BSE
- Share Price₹20.99
-0.05% today
- Revenue₹16.98 Cr
FY 2025-26 · +26.2% YoY
- EBITDA−₹0.31 Cr
Margin -1.8%
- Net Profit₹0.96 Cr
FY 2025-26 · +155.2% YoY
- P/E (TTM)31.4x
P/B 2.0x
- ROE22.2%
ROCE 0.0%
Associated legal entities of Brawnpharma
Brawnpharma operates through Brawn Biotech Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Brawn Biotech Limited Listed CIN L74899DL1985PLC022468 | Active | 07 Nov 1985 | Delhi, Delhi | ₹17.4 Cr | 17 | 5 | View details |
Board of directors of Brawn Biotech Limited (Brawnpharma)
Brawn Biotech Limited is the primary company behind Brawnpharma. The board of Brawn Biotech Limited currently have 3 directors; the longest-serving is Brij Raj Gupta, appointed in 1985. 19 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Brij Raj Gupta DIN 00974969 | Director | 07 Nov 1985 | 41 yrs | Brawn Biotech Limited |
| Mayank Jain DIN 07993851 | Director | 27 Aug 2024 | 2 yrs 2 mo | Brawn Biotech Limited |
| Pooja Jha DIN 10749145 | Director | 27 Aug 2024 | 2 yrs 2 mo | Brawn Biotech Limited |
IPO & Listings of Brawnpharma
Brawnpharma is a publicly listed company on the BSE with ticker symbol BRAWN in India, operating in the Pharmaceuticals sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- Listed onBSE: BRAWN
- Listed entityBrawn Biotech Limited
- Exchange sectorPharmaceuticals
Financials of Brawnpharma
Exchange-reported figures of Brawn Biotech Limited, the listed company behind Brawnpharma (BSE: BRAWN).
Financial Highlights
FY 2025-26 Β· StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 16.98 | 13.46 | 16.49 | 22.23 | 8.62 | 34.98 | 49.62 |
| Revenue growth | +26.2% | -18.4% | -25.8% | +157.9% | -75.4% | -29.5% | - |
| EBITDA | (0.31) | (1.78) | (1.47) | (0.29) | (2.00) | (0.59) | 0.74 |
| EBITDA margin | -1.8% | -13.2% | -8.9% | -1.3% | -23.2% | -1.7% | +1.5% |
| Profit before tax | 0.02 | (1.80) | (1.54) | (0.40) | (2.11) | (0.35) | 0.83 |
| Net profit | 0.96 | (1.74) | (1.23) | (0.85) | (1.64) | (0.55) | 0.60 |
| Net profit margin | +5.7% | -12.9% | -7.5% | -3.8% | -19.0% | -1.6% | +1.2% |
| EPS (βΉ) | 3.14 | (5.80) | (4.16) | (2.89) | (5.48) | (1.84) | 1.97 |
| Balance sheet | |||||||
| Total assets | 5.69 | 11.16 | 8.08 | 6.48 | 7.46 | 8.97 | 9.37 |
| Net worth | 4.34 | 3.36 | 5.06 | 6.31 | 7.22 | 8.79 | 9.26 |
| Total debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash & bank | 0.28 | 0.20 | 0.40 | 0.44 | 0.22 | 0.40 | 0.40 |
| Net working capital | 1.95 | 8.18 | 6.63 | 5.35 | 5.86 | 7.83 | 8.29 |
| Cash flow | |||||||
| Cash from operations | 0.77 | 0.05 | (0.03) | 0.32 | 0.19 | 0.03 | (0.08) |
| Cash from investing | (0.03) | (0.24) | (0.01) | (0.10) | (0.30) | 0.00 | (0.02) |
| Cash from financing | 0.00 | 0.00 | 0.00 | (0.01) | (0.06) | (0.04) | (0.05) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5.62 | 6.08 | 1.98 | 4.31 | 4.89 | 5.80 | 2.26 | 3.84 |
| Revenue growth (YoY) | +14.9% | +4.8% | -12.4% | +12.2% | +48.2% | +42.9% | - | - |
| Other income | 0.14 | 0.14 | 0.18 | 0.09 | 0.09 | 0.09 | 0.09 | 0.00 |
| Total expenses | 5.70 | 6.03 | 2.48 | 4.32 | 4.88 | 5.62 | 2.81 | 4.25 |
| EBITDA | (0.08) | 0.05 | (0.50) | (0.01) | 0.01 | 0.18 | (0.55) | (0.41) |
| EBITDA margin | -1.4% | +0.8% | -25.3% | -0.2% | +0.2% | +3.1% | -24.3% | -10.7% |
| Depreciation | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.03 | 0.16 | (0.35) | 0.05 | 0.07 | 0.24 | (0.49) | (0.44) |
| Tax | 0.00 | 0.00 | (0.94) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5.62 | 6.08 | 1.98 | 4.31 | 4.89 | 5.80 | 2.26 | 3.84 |
| Revenue growth (YoY) | +14.9% | +4.8% | -12.4% | +12.2% | +48.2% | +42.9% | - | - |
| Other income | 0.14 | 0.14 | 0.18 | 0.09 | 0.09 | 0.09 | 0.09 | 0.00 |
| Total expenses | 5.70 | 6.03 | 2.48 | 4.32 | 4.88 | 5.62 | 2.81 | 4.25 |
| EBITDA | (0.08) | 0.05 | (0.50) | (0.01) | 0.01 | 0.18 | (0.55) | (0.41) |
| EBITDA margin | -1.4% | +0.8% | -25.3% | -0.2% | +0.2% | +3.1% | -24.3% | -10.7% |
| Depreciation | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.03 | 0.16 | (0.35) | 0.05 | 0.07 | 0.24 | (0.49) | (0.44) |
| Tax | 0.00 | 0.00 | (0.94) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 16.98 | 13.46 | 16.49 | 22.23 | 8.62 | 34.98 | 49.62 |
| Revenue growth | +26.2% | -18.4% | -25.8% | +157.9% | -75.4% | -29.5% | - |
| Other income | 0.45 | 0.09 | 0.09 | 0.01 | 0.00 | 0.31 | 0.17 |
| Total expenses | 17.29 | 15.24 | 17.96 | 22.52 | 10.62 | 35.57 | 48.88 |
| Employee cost | 0.68 | 1.13 | 1.40 | 1.40 | 1.80 | 2.36 | 3.08 |
| EBITDA | (0.31) | (1.78) | (1.47) | (0.29) | (2.00) | (0.59) | 0.74 |
| EBITDA margin | -1.8% | -13.2% | -8.9% | -1.3% | -23.2% | -1.7% | +1.5% |
| Depreciation | 0.12 | 0.11 | 0.10 | 0.11 | 0.05 | 0.03 | 0.03 |
| Interest | 0.00 | 0.00 | 0.06 | 0.01 | 0.06 | 0.04 | 0.05 |
| Profit before tax | 0.02 | (1.80) | (1.54) | (0.40) | (2.11) | (0.35) | 0.83 |
| Tax | (0.94) | (0.06) | (0.30) | 0.45 | (0.47) | 0.20 | 0.23 |
| Net profit | 0.96 | (1.74) | (1.23) | (0.85) | (1.64) | (0.55) | 0.60 |
| Net profit margin | +5.7% | -12.9% | -7.5% | -3.8% | -19.0% | -1.6% | +1.2% |
| EPS (βΉ) | 3.14 | (5.80) | (4.16) | (2.89) | (5.48) | (1.84) | 1.97 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
| Reserves & surplus | 1.34 | 0.36 | 2.06 | 3.31 | 4.22 | 5.79 | 6.26 |
| Shareholders' funds (net worth) | 4.34 | 3.36 | 5.06 | 6.31 | 7.22 | 8.79 | 9.26 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total liabilities | 5.69 | 11.16 | 8.08 | 6.48 | 7.46 | 8.97 | 9.37 |
| Assets | |||||||
| Gross block | 1.05 | 1.02 | 0.78 | 0.77 | 0.67 | 0.38 | 0.38 |
| Net block | 0.36 | 0.46 | 0.33 | 0.37 | 0.38 | 0.14 | 0.18 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 10.06 | 10.47 | 6.02 | 4.79 | 4.72 | 0.26 | 0.39 |
| Sundry debtors | 3.55 | 3.41 | 3.88 | 5.32 | 2.81 | 9.28 | 15.00 |
| Cash & bank balances | 0.28 | 0.20 | 0.40 | 0.44 | 0.22 | 0.40 | 0.40 |
| Loans & advances | 3.23 | 3.43 | 2.84 | 2.85 | 4.43 | 2.79 | 3.42 |
| Total current assets | 17.12 | 17.51 | 13.14 | 13.40 | 12.18 | 12.73 | 19.21 |
| Total current liabilities | 15.17 | 9.33 | 6.51 | 8.05 | 6.32 | 4.90 | 10.92 |
| Net working capital | 1.95 | 8.18 | 6.63 | 5.35 | 5.86 | 7.83 | 8.29 |
| Total assets | 5.69 | 11.16 | 8.08 | 6.48 | 7.46 | 8.97 | 9.37 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.20 | 0.00 | 0.44 | 0.22 | 0.40 | 0.40 | 0.54 |
| Net cash from operating activities | 0.77 | 0.05 | (0.03) | 0.32 | 0.19 | 0.03 | (0.08) |
| Net cash from investing activities | (0.03) | (0.24) | (0.01) | (0.10) | (0.30) | 0.00 | (0.02) |
| Net cash from financing activities | 0.00 | 0.00 | 0.00 | (0.01) | (0.06) | (0.04) | (0.05) |
| Net change in cash | 0.74 | (0.20) | (0.04) | 0.21 | (0.17) | 0.00 | (0.14) |
| Closing cash | 0.28 | 0.20 | 0.40 | 0.44 | 0.22 | 0.40 | 0.40 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +26.2% | -18.4% | -25.8% | +157.9% | -75.4% | -29.5% | - |
| EBITDA growth | +82.6% | -21.1% | -406.9% | +85.5% | -239.0% | -179.7% | - |
| PBT growth | +9998.0% | -16.9% | -285.0% | +81.0% | -502.9% | - | -54.4% |
| Net income growth | +155.2% | -41.5% | -44.7% | +48.2% | -198.2% | -191.7% | - |
| Revenue CAGR (3Y) | -8.6% | +16.0% | -22.2% | -23.5% | -49.1% | -14.4% | -6.4% |
| EBITDA CAGR (3Y) | +2.3% | -3.8% | +35.6% | - | - | - | -15.6% |
| Profitability & leverage | |||||||
| Net income margin | +5.7% | -12.9% | -7.5% | -3.8% | -19.0% | -1.6% | +1.2% |
| Return on capital employed | 0.0% | 0.0% | -20.5% | -5.7% | -25.0% | -3.5% | +9.6% |
| Return on net worth | +22.2% | 0.0% | -22.0% | -12.9% | -20.5% | -6.1% | +6.6% |
| Debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | 0.00 | 0.00 | -3.82 | -2.50 | -2.93 | -6.45 | 7.04 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 16.41 | 14.96 | 21.28 | 30.88 | 16.42 | 92.05 | 132.32 |
| Inventory turnover | 1.65 | 1.63 | 3.05 | 4.68 | 3.46 | 107.63 | 135.95 |
| Debtors turnover | 4.88 | 3.69 | 3.58 | 5.47 | 1.43 | 2.88 | 3.15 |
| EPS (βΉ) | 3.14 | (5.80) | (4.16) | (2.89) | (5.48) | (1.84) | 1.97 |
| Dividend per share (βΉ) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (βΉ) | 14.46 | 11.21 | 16.88 | 21.03 | 24.07 | 29.31 | 30.87 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Brawnpharma
Complete news archive for Brawnpharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Brawnpharma
Brawnpharma was founded in 1985.
Brawnpharma is headquartered in Delhi, India. It is registered at Delhi, Delhi, India.
The primary company behind Brawnpharma, Brawn Biotech Limited, reported revenue of βΉ17.43 Cr for FY 2026, up 26% year on year.
Brawnpharma was established in 1985 in Delhi, India, within the pharmaceutical sector. Operations are centered on the development, manufacturing, and distribution of medicinal products. Services include formulation and supply to healthcare markets. The company is headquartered in Delhi, with activities spanning the Indian pharmaceutical industry. Limited public details are available regarding specific product lines or expansions.
Yes, Brawnpharma is publicly traded on BSE under the ticker symbol BRAWN.
Brawnpharma operates through Brawn Biotech Limited.
The legal entities of Brawnpharma currently have 5 directors, including Brij Raj Gupta, Priyanka Sharma, Mayank Jain and others.
